🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
TherapeuticsMD, Inc. (TXMD)
NASDAQ: TXMD · Real-Time Price · USD
1.710
-0.100 (-5.52%)
At close: Nov 20, 2026, 4:00 PM EST
1.709
-0.001 (-0.06%)
After-hours: Nov 20, 2026, 7:50 PM EST

TherapeuticsMD Statistics

Total Valuation

TherapeuticsMD has a market cap or net worth of $19.79 million. The enterprise value is $13.56 million.

Market Cap19.79M
Enterprise Value 13.56M

Important Dates

The last earnings date was Friday, November 13, 2026, after market close.

Earnings Date Nov 13, 2026
Ex-Dividend Date n/a

Share Statistics

TherapeuticsMD has 11.57 million shares outstanding. The number of shares has increased by 0.59% in one year.

Current Share Class 11.57M
Shares Outstanding 11.57M
Shares Change (YoY) +0.59%
Shares Change (QoQ) n/a
Owned by Insiders (%) 2.20%
Owned by Institutions (%) 23.16%
Float 9.49M

Valuation Ratios

The trailing PE ratio is 162.24.

PE Ratio 162.24
Forward PE n/a
PS Ratio 5.28
Forward PS n/a
PB Ratio 0.72
P/TBV Ratio 0.82
P/FCF Ratio 5.94
P/OCF Ratio 5.94
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

EV / Earnings 111.11
EV / Sales 3.62
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF 4.07

Financial Position

The company has a current ratio of 3.32, with a Debt / Equity ratio of 0.15.

Current Ratio 3.32
Quick Ratio 2.64
Debt / Equity 0.15
Debt / EBITDA n/a
Debt / FCF 1.26
Interest Coverage n/a

Financial Efficiency

Return on equity (ROE) is 0.57% and return on invested capital (ROIC) is -5.22%.

Return on Equity (ROE) 0.57%
Return on Assets (ROA) 0.32%
Return on Invested Capital (ROIC) -5.22%
Return on Capital Employed (ROCE) -4.32%
Weighted Average Cost of Capital (WACC) 6.38%
Revenue Per Employee $3.75M
Profits Per Employee $122,000
Employee Count1
Asset Turnover 0.10
Inventory Turnover n/a

Taxes

In the past 12 months, TherapeuticsMD has paid $32,000 in taxes.

Income Tax 32,000
Effective Tax Rate 17.02%

Stock Price Statistics

The stock price has increased by +3.64% in the last 52 weeks. The beta is 0.63, so TherapeuticsMD's price volatility has been lower than the market average.

Beta (5Y) 0.63
52-Week Price Change +3.64%
50-Day Moving Average 1.94
200-Day Moving Average 2.07
Relative Strength Index (RSI) 40.25
Average Volume (20 Days) 19,365

Short Selling Information

The latest short interest is 31,319, so 0.27% of the outstanding shares have been sold short.

Short Interest 31,319
Short Previous Month 24,664
Short % of Shares Out 0.27%
Short % of Float 0.33%
Short Ratio (days to cover) 1.65

Income Statement

In the last 12 months, TherapeuticsMD had revenue of $3.75 million and earned $122,000 in profits. Earnings per share was $0.01.

Revenue3.75M
Gross Profit 3.75M
Operating Income -1.41M
Pretax Income 188,000
Net Income 122,000
EBITDA -1.03M
EBIT -1.41M
Earnings Per Share (EPS) $0.01
Full Income Statement

Balance Sheet

The company has $10.45 million in cash and $4.21 million in debt, with a net cash position of $6.24 million or $0.54 per share.

Cash & Cash Equivalents 10.45M
Total Debt 4.21M
Net Cash 6.24M
Net Cash Per Share $0.54
Equity (Book Value) 27.62M
Book Value Per Share 2.39
Working Capital 12.17M
Full Balance Sheet

Cash Flow

Operating Cash Flow 3.33M
Capital Expenditures n/a
Depreciation & Amortization 383,000
Net Borrowing n/a
Free Cash Flow 3.33M
FCF Per Share $0.29
Full Cash Flow Statement

Margins

Gross margin is 100.00%, with operating and profit margins of -37.73% and 3.26%.

Gross Margin 100.00%
Operating Margin -37.73%
Pretax Margin 5.02%
Profit Margin 3.26%
EBITDA Margin -27.50%
EBIT Margin -37.73%
FCF Margin 88.97%

Dividends & Yields

TherapeuticsMD does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
FCF Payout Ratio n/a
Buyback Yield -0.59%
Shareholder Yield -0.59%
Earnings Yield 0.62%
FCF Yield 16.83%

Analyst Forecast

Price Target n/a
Price Target Difference n/a
Analyst Consensus n/a
Analyst Count n/a
Revenue Growth Forecast (3Y) 47.51%
EPS Growth Forecast (3Y) n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside
Graham Formula Value
Graham Formula Upside

Stock Splits

The last stock split was on May 9, 2022. It was a reverse split with a ratio of 1:50.

Last Split Date May 9, 2022
Split Type Reverse
Split Ratio 1:50

Scores

Altman Z-Score n/a
Piotroski F-Score 6